Stuart Therapeutics has collected equity financing from investors including Wisconsin Alumni Research Foundation to fund phase 2 trials for a drug aimed at dry eye disease.

First American Financial and Shea Ventures contributed to a round that reportedly made the second-hand home marketplace the fastest US company so far to achieve unicorn status.

The Petronas and TNSC-backed 3D printing tedchnology provider has agreed to list through a reverse takeover deal at a $1.6bn valuation.

Citi’s strategic investment vehicle helped fill out a series D round valuing the risk management software developer above $1bn.

New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.

Bayer could exit the drug discovery technology developer should it complete an initial public offering on the Nasdaq Global Select Market.

Stefanie Tompkins, Colorado School of Mines’ vice-president for research and technology transfer, has been appointed director of Darpa.

Axelys will become the successor to three separate tech transfer organisations in Quebec next month.

The Novartis-backed gene therapy developer will merge with Chardan Healthcare Acquisition 2 Corp and take a New York Stock Exchange listing.

Asher Bio has launched with $55m in series A financing to commercialise research partially conducted at WashU and Leiden.